リボミック raised its standalone earnings forecast for the fiscal year ending March 2027. Revenue was revised from ¥17 million to ¥26 million, while both the operating loss and net loss narrowed. The revision was driven by expected consideration of approximately ¥830 million under a technology agreement with an overseas biotech company.
After the close of trading on the 20th, リボミック raised its standalone earnings forecast for the fiscal year ending March 2027. Revenue was revised from the previous forecast of ¥17 million to ¥26 million, while the operating outlook changed from an expected widening loss to a substantially narrower loss. The net loss is also expected to narrow.
The company announced that it plans to enter into a technology evaluation agreement relating to DDS aptamer technology with an overseas biotech company. It is scheduled to receive approximately ¥83 million in consideration, which was cited as a factor behind the earnings revision.
Research and development expenses, including the cost of preclinical studies for R&BＭ-006, are expected to come in below assumptions. A reduction in taxes and other dues associated with the reduction in capital is also expected to contribute to the improvement in results.